Application of proteomic profiling based on 2D-DIGE for classification of compounds according to the mechanism of action

Chem Biol. 2010 May 28;17(5):460-70. doi: 10.1016/j.chembiol.2010.03.016.

Abstract

The development of new anticancer agents derived from natural resources requires a rapid identification of their molecular mechanism of action. To make this step short, we have initiated the proteomic profiling of HeLa cells treated with anticancer drugs representing a wide spectrum of mechanisms of action using two-dimensional difference gel electrophoresis (2D-DIGE). Unique proteome patterns were observed in HeLa cells treated with the HSP90 inhibitor geldanamycin, and were similar to the patterns induced by radicicol, a structurally different HSP90 inhibitor. On the other hand, etoposide and ICRF-193, compounds claimed to be topoisomerase II inhibitors, showed different proteomic profiles, which reflect their different biological activities as revealed by cell-cycle analysis. Thus far, combined data from 19 compounds have allowed their successful classification by cluster analysis according to the mechanism of action.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / classification*
  • Antineoplastic Agents / pharmacology
  • Benzoquinones / pharmacology
  • Cluster Analysis
  • DNA Topoisomerases, Type II / metabolism
  • Electrophoresis, Gel, Two-Dimensional / methods*
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors
  • HSP90 Heat-Shock Proteins / metabolism
  • HeLa Cells
  • Humans
  • Lactams, Macrocyclic / pharmacology
  • Macrolides / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Proteome / analysis*
  • Topoisomerase II Inhibitors

Substances

  • Antineoplastic Agents
  • Benzoquinones
  • HSP90 Heat-Shock Proteins
  • Lactams, Macrocyclic
  • Macrolides
  • Protein Kinase Inhibitors
  • Proteome
  • Topoisomerase II Inhibitors
  • DNA Topoisomerases, Type II
  • monorden
  • geldanamycin